Final answer:
CKD patients should begin NaHCO3 therapy when acidosis and sodium depletion occur due to the kidneys' reduced ability to reabsorb sodium and buffer acids. NaHCO3 helps correct the bicarbonate deficit and neutralize excess acid, which is important for managing CKD progression. Close monitoring by physicians is essential to avoid side effects.
Step-by-step explanation:
CKD patients should start NaHCO3 therapy when they have acidosis, and there is a sodium depletion due to poor renal reabsorption and loss of sodium in buffering acids. The initiation of NaHCO3 helps to correct acidosis, thereby improving renal function and potentially slowing the progression of chronic kidney disease (CKD).
Sodium Bicarbonate (NaHCO3) is often prescribed to CKD patients to counteract acidosis. Acidosis is a common complication in CKD, where the kidneys can't effectively excrete the acid load, leading to a systemic decrease in bicarbonate levels and a concurrent increase in hydrogen ion concentration. This situation is compounded when there is simultaneous sodium depletion, as the kidneys' ability to reabsorb sodium is compromised in CKD, which can further exacerbate acidosis.
During this condition, administering NaHCO3 can replenish the bicarbonate deficit, thus aiding in the neutralization of excess acid. It's important to closely monitor electrolytes and blood pH levels, as administering NaHCO3 can lead to potential side effects such as metabolic alkalosis if not properly managed. Physicians typically recommend starting NaHCO3 therapy when the plasma bicarbonate level falls below a certain threshold or when metabolic acidosis is identified.